As cancer researchers expand the frontiers of their understanding of the basic science of cancer, biotech companies are using what they’ve already learned to mobilize the human immune system against cancer.
One of the most exciting developments are cancer vaccines. Scientists are using artificial intelligence to identify mutations in cancerous tumors that the im-mune system can recognize, then creating personalized vaccines designed to prime a patient’s immune system to hunt them down and destroy them.
In 2017, Moderna, in partnership with
